439 related articles for article (PubMed ID: 28686510)
1. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
3. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified?
Sharma P; Arora S; Mukherjee A; Pal S; Sahni P; Garg P; Khadgawat R; Thulkar S; Bal C; Kumar R
Clin Nucl Med; 2014 Jan; 39(1):37-43. PubMed ID: 24152621
[TBL] [Abstract][Full Text] [Related]
6. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
[TBL] [Abstract][Full Text] [Related]
8. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India.
Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H
J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479
[TBL] [Abstract][Full Text] [Related]
9.
Sakthivel P; Kumar R; Arunraj ST; Bhalla AS; Prashanth A; Kumar R; Sharma SC; Thakar A
Laryngoscope; 2021 Jul; 131(7):1509-1515. PubMed ID: 33355921
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Somatostatin Receptor 1-5 Expression, [
Majala S; Vesterinen T; Seppänen H; Mustonen H; Sundström J; Schalin-Jäntti C; Gullichsen R; Schildt J; Kemppainen J; Arola J; Kauhanen S
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008325
[TBL] [Abstract][Full Text] [Related]
13. The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm.
Rufini V; Inzani F; Stefanelli A; Castaldi P; Perotti G; Cinquino A; Indovina L; Rindi G
Pancreas; 2017 Feb; 46(2):157-163. PubMed ID: 27846139
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of atypical
Gossili F; Almasi CE; Zacho HD
Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
[TBL] [Abstract][Full Text] [Related]
15. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic values of
Kumar R; Vankadari K; Mittal BR; Bansal D; Trehan A; Sahu JK; Sankhyan N
Eur Radiol; 2021 Jul; 31(7):4587-4594. PubMed ID: 33409780
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
18. Comparison of diagnostic efficacy of
Zhang B; He Q; Long Y; Zhang Y; Wang X; Chen Z; Liu J; Zhang X
Front Endocrinol (Lausanne); 2022; 13():962800. PubMed ID: 36213295
[TBL] [Abstract][Full Text] [Related]
19. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
20. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.
Berzaczy D; Giraudo C; Haug AR; Raderer M; Senn D; Karanikas G; Weber M; Mayerhoefer ME
Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]